Associate Scientist II, Analytical Development, Bioassay
Posted on: 7 Feb 2021
Cambridge, MA
Job Description
Job Description
The successful candidate will support development, improvement, qualification, execution, and troubleshooting of various biological assays for characterization of the AAV gene therapy and protein biologics. The scientist will also assist in implementation of new technologies.
Responsibilities
The individual will perform cell-based assays to measure viral vector infectivity, transgene expression, and functional potency with broad variety of readouts such as qPCR/ddPCR, MSD- or DELFIA-based immunoassays, ELISA, luminescence, high content imaging, FACS etc. He/she might also help support genome titer and process-related impurity assessment. Responsibilities include data analysis, report writing and reviewing, internal technical presentations. The scientist will also be involved in new technology evaluation and implementation.
Qualifications
* Solid understanding of Cell and Molecular Biology
* Experience with mammalian cell culture and PCR is required
* Hands-on experience with bioassays in 96-well format and multichannel pipetting is strongly preferred
* Experience with AAV or lentiviruses is highly desirable
* Familiarity with statistical analysis for biological assays and automation is a plus
* Excellent laboratory, computer, documentation, and organization skills
* The ideal candidate is a fast learner with strong scientific curiosity, good interpersonal skills, and attention to detail.
Education:
B.S.in Molecular/Cell Biology, Virology, or related Biological Sciences with 0-2 years of experience.
Additional Information
The successful candidate will support development, improvement, qualification, execution, and troubleshooting of various biological assays for characterization of the AAV gene therapy and protein biologics. The scientist will also assist in implementation of new technologies.
Biogen
Cambridge, MA
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.
Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.
The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
-
IndustryBiotechnology
-
No. of Employees7,800
-
Website
-
Jobs Posted445
